Identification of MMP1 as a potential gene conferring erlotinib resistance in non-small cell lung cancer based on bioinformatics analyses

BACKGROUND: Non-small cell lung cancer (NSCLC) is the major type of lung cancer with high morbidity and poor prognosis. Erlotinib, an inhibitor of epidermal growth factor receptor (EGFR), has been clinically applied for NSCLC treatment. Nevertheless, the erlotinib acquired resistance of NSCLC occurs...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Huyue, Xiang, Qiumei, Hu, Changpeng, Zhang, Jing, Zhang, Qian, Zhang, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379796/
https://www.ncbi.nlm.nih.gov/pubmed/32703314
http://dx.doi.org/10.1186/s41065-020-00145-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379796/
https://www.ncbi.nlm.nih.gov/pubmed/32703314
http://dx.doi.org/10.1186/s41065-020-00145-x

Ejemplares similares